Overview
A Pharmaceutical Company, the licensee, sued its licensor for patent invalidity – while paying a license. The licensee had little reason not to pursue the suit because they risked only their legal fees. The licensor, therefore, decided to raise the stakes for the licensee by cancelling their license and countersuing for breach of contract and infringement.
Our Role
As part of the technology tutorial, we needed to clearly explain the complementary-determining regions (CDRs) that were at the heart of the patented humanized immunoglobulin process. We achieved this by creating a unique, scientifically acceptable portrayal of antibody structure that was ideally suited to explain of the structure in question.
